EP3782987A4 - Benzopyrazole compound used as rho kinase inhibitor - Google Patents
Benzopyrazole compound used as rho kinase inhibitor Download PDFInfo
- Publication number
- EP3782987A4 EP3782987A4 EP19788388.7A EP19788388A EP3782987A4 EP 3782987 A4 EP3782987 A4 EP 3782987A4 EP 19788388 A EP19788388 A EP 19788388A EP 3782987 A4 EP3782987 A4 EP 3782987A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- compound used
- kinase inhibitor
- rho kinase
- benzopyrazole
- benzopyrazole compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810349362 | 2018-04-18 | ||
CN201811221303 | 2018-10-19 | ||
PCT/CN2019/083210 WO2019201297A1 (en) | 2018-04-18 | 2019-04-18 | Benzopyrazole compound used as rho kinase inhibitor |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3782987A1 EP3782987A1 (en) | 2021-02-24 |
EP3782987A4 true EP3782987A4 (en) | 2021-05-19 |
Family
ID=68239949
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19788388.7A Pending EP3782987A4 (en) | 2018-04-18 | 2019-04-18 | Benzopyrazole compound used as rho kinase inhibitor |
Country Status (5)
Country | Link |
---|---|
US (1) | US11345678B2 (en) |
EP (1) | EP3782987A4 (en) |
JP (1) | JP7187575B2 (en) |
CN (1) | CN112020496B (en) |
WO (1) | WO2019201297A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021038419A1 (en) * | 2019-08-23 | 2021-03-04 | Insilico Medicine Ip Limited | Kinase inhibitors and methods of synthesis and treatment |
US11702400B2 (en) * | 2019-10-18 | 2023-07-18 | Medshine Discovery Inc. | Salt types, crystal forms, and preparation methods for benzopyrazole compounds as RHO kinase inhibitors |
CN116438175A (en) * | 2020-11-11 | 2023-07-14 | 南京明德新药研发有限公司 | Benzourea ring derivative and preparation method and application thereof |
CN113214172A (en) * | 2021-04-25 | 2021-08-06 | 西南大学 | Preparation method of fluconazole intermediate reductive amination product |
CN114181139B (en) * | 2021-12-27 | 2023-12-08 | 四川仁安药业有限责任公司 | Synthesis method of 5-halogenated nicotinic acid |
WO2024209363A1 (en) | 2023-04-06 | 2024-10-10 | Pfizer Inc. | Substituted indazole propionic acid derivative compounds and uses thereof as ampk activators |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007519754A (en) | 2004-01-30 | 2007-07-19 | スミスクライン ビーチャム コーポレーション | Compound |
CR9465A (en) | 2005-03-25 | 2008-06-19 | Surface Logix Inc | PHARMACOCINETICALLY IMPROVED COMPOUNDS |
US20070208053A1 (en) | 2006-01-19 | 2007-09-06 | Arnold Lee D | Fused heterobicyclic kinase inhibitors |
CA2700988A1 (en) | 2006-09-27 | 2008-05-08 | Surface Logix, Inc. | Rho kinase inhibitors |
CN101790526A (en) | 2007-06-08 | 2010-07-28 | 雅培制药有限公司 | 5-heteroaryl substituted indazoles as kinase inhibitors |
US8445686B2 (en) | 2007-08-27 | 2013-05-21 | Abbvie Inc. | 4-(4-pyridinyl)-benzamides and their use as rock activity modulators |
US20120202793A1 (en) | 2009-03-09 | 2012-08-09 | Paul Sweetnam | Rho kinase inhibitors |
ES2556350T3 (en) * | 2009-08-10 | 2016-01-15 | Samumed, Llc | Indazole inhibitors of the Wnt signaling pathway and its therapeutic uses |
WO2011050245A1 (en) | 2009-10-23 | 2011-04-28 | Yangbo Feng | Bicyclic heteroaryls as kinase inhibitors |
WO2012135697A2 (en) | 2011-03-30 | 2012-10-04 | H. Lee Moffitt Cancer Center & Research Institute Inc. | Novel rho kinase inhibitors and methods of use |
HRP20220913T1 (en) | 2012-10-05 | 2022-10-28 | Kadmon Corporation, Llc | Rho kinase inhibitors |
AR094929A1 (en) | 2013-02-28 | 2015-09-09 | Bristol Myers Squibb Co | DERIVATIVES OF PHENYLPIRAZOL AS POWERFUL INHIBITORS OF ROCK1 AND ROCK2 |
WO2016028971A1 (en) | 2014-08-21 | 2016-02-25 | Bristol-Myers Squibb Company | Tied-back benzamide derivatives as potent rock inhibitors |
AU2017351216C1 (en) | 2016-10-24 | 2021-10-14 | Translational Drug Development, Llc | Amide compounds as kinase inhibitors |
-
2019
- 2019-04-18 JP JP2020557966A patent/JP7187575B2/en active Active
- 2019-04-18 CN CN201980026510.7A patent/CN112020496B/en active Active
- 2019-04-18 US US17/047,840 patent/US11345678B2/en active Active
- 2019-04-18 EP EP19788388.7A patent/EP3782987A4/en active Pending
- 2019-04-18 WO PCT/CN2019/083210 patent/WO2019201297A1/en unknown
Non-Patent Citations (1)
Title |
---|
No further relevant documents disclosed * |
Also Published As
Publication number | Publication date |
---|---|
EP3782987A1 (en) | 2021-02-24 |
JP7187575B2 (en) | 2022-12-12 |
US20210371393A1 (en) | 2021-12-02 |
JP2021522201A (en) | 2021-08-30 |
CN112020496B (en) | 2023-04-28 |
WO2019201297A1 (en) | 2019-10-24 |
US11345678B2 (en) | 2022-05-31 |
CN112020496A (en) | 2020-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3656769A4 (en) | Aryl-phosphorus-oxygen compound as egfr kinase inhibitor | |
EP3752491A4 (en) | Heterocyclic compounds as kinase inhibitors | |
EP3836923A4 (en) | Pyrrolo - dipyridine compounds | |
EP3806858A4 (en) | Kinase inhibitor salts and compositions thereof | |
EP3843714A4 (en) | Cd73 inhibitors | |
EP3782987A4 (en) | Benzopyrazole compound used as rho kinase inhibitor | |
EP3889150A4 (en) | Compound serving as irak inhibitor | |
EP3733671A4 (en) | Amino-fluoropiperidine derivative as kinase inhibitor | |
EP3804707A4 (en) | Kinase inhibitor | |
EP3464275A4 (en) | Egfr inhibitor compounds | |
IL276269A (en) | Aminopyrrolotriazines as kinase inhibitors | |
EP3787635A4 (en) | Cd73 inhibitors | |
EP3902805A4 (en) | Cyclin-dependent kinase inhibitors | |
EP3733673A4 (en) | Oxy-fluoropiperidine derivative as kinase inhibitor | |
EP3817736A4 (en) | Pikfyve inhibitors | |
EP4003993A4 (en) | Substituted 2-morpholinopyridine derivatives as atr kinase inhibitors | |
EP3999072A4 (en) | Boron-containing rho kinase inhibitors | |
EP4003986A4 (en) | Inhibitor compounds | |
EP3927700A4 (en) | Kinase inhibitors | |
GB201819126D0 (en) | Inhibitor compounds | |
EP3532479A4 (en) | Amide compounds as kinase inhibitors | |
EP3749646A4 (en) | Heteroaryl compounds as kinase inhibitor | |
EP3819299A4 (en) | Hypoxanthine compound | |
EP3638237A4 (en) | Aminothiazole compounds as protein kinase inhibitors | |
GB201914860D0 (en) | Inhibitor compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20201117 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20210420 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07D 231/56 20060101AFI20210414BHEP Ipc: C07D 401/04 20060101ALI20210414BHEP Ipc: C07D 403/04 20060101ALI20210414BHEP Ipc: C07D 403/12 20060101ALI20210414BHEP Ipc: A61K 31/416 20060101ALI20210414BHEP Ipc: A61P 11/00 20060101ALI20210414BHEP |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20230214 |